Brandon B. Boze
Director at CBRE
Board
About Brandon B. Boze
Brandon B. Boze, age 44, has served on CBRE’s board since December 2012 and is an independent director; he currently serves on the Audit and Executive Committees. He is Managing Principal of Bridges Capital LLC (founded in 2024), previously served as Independent Chair of CBRE’s Board from May 2018 to November 2023, was President/Partner at ValueAct Capital from August 2005 to January 2024, and earlier worked as an investment banker at Lehman Brothers. He holds a B.E. from Vanderbilt University and is a CFA charterholder; he has no current public company directorships.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| CBRE Group, Inc. | Independent Chair of the Board | May 2018 – Nov 2023 | Led the board as independent chair; governance leadership transition in Nov 2023. |
| Bridges Capital LLC | Managing Principal | 2024 – Present | Commercial real estate investments in San Francisco Bay Area. |
| ValueAct Capital | President, Partner, Management Committee Member | Aug 2005 – Jan 2024 | Finance, strategy, M&A, and investments expertise. |
| Lehman Brothers | Investment Banker | Prior to joining ValueAct | Finance and transaction experience. |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| None (Current Public Boards) | — | — | CBRE proxy states no other public boards currently. |
| Trinity Industries, Inc. | Director (Prior) | Not disclosed | Prior public company board service. |
| Valeant Pharmaceuticals International | Director (Prior) | Not disclosed | Prior public company board service. |
Board Governance
- Independence: Independent director; CBRE board nominees are 80% independent, with independence assessed under NYSE standards and CBRE Categorical Independence Standards.
- Committee assignments: Audit Committee member; Executive Committee member (Executive Committee held no formal meetings in 2024 and acted twice by unanimous written consent).
- Attendance: In 2024, each incumbent director attended at least 75% of board and committee meetings on which they served; the board met eight times, Audit met nine, Compensation four, Governance five.
- Tenure and demographics: Board tenure 12 years; age 44.
- Lead Independent Director and executive sessions: Shira D. Goodman is Lead Independent Director and chairs Executive Committee; non-management directors meet in executive session at each regularly scheduled board meeting.
- Overboarding policy: Directors who are not public company executive officers may serve on no more than five public company boards (four if chair/lead independent), and CBRE highlights no over-boarding among directors.
Fixed Compensation
| Year | Fees Earned or Paid in Cash ($) | Notes |
|---|---|---|
| 2024 | 110,000 | Includes annual board service retainer and any committee service; Boze is not a committee chair. |
Performance Compensation
| Grant Date | Award Type | Shares Granted | Grant-Date Fair Value ($) | Vesting Terms | Options Outstanding |
|---|---|---|---|---|---|
| May 22, 2024 | RSUs | 2,455 | 219,993 | Vests in full on earlier of one-year anniversary or next annual meeting. | None (no option awards outstanding). |
Performance metrics tied to director compensation: None disclosed (director RSUs are time-based, not performance-conditioned).
Other Directorships & Interlocks
| Type | Company | Relationship | Potential Interlock/Conflict Noted |
|---|---|---|---|
| Current public boards | None | — | None. |
| Prior public boards | Trinity Industries, Inc. | Former Director | No CBRE-related party exposure disclosed in 2024. |
| Prior public boards | Valeant Pharmaceuticals International | Former Director | No CBRE-related party exposure disclosed in 2024. |
- Related-party transactions: CBRE reports no related-party transactions involving directors in 2024, other than items specific to other individuals (Clancy, Hodari).
- Policy oversight: Audit Committee reviews and approves interested person transactions under CBRE’s related-party transactions and corporate opportunities policy.
Expertise & Qualifications
- Skills highlighted: Finance and Accounting; Global Business Operations; Human Capital Management; M&A; Other Public Company Board Service; Real Estate Industry Experience; Risk Management; Senior Leadership/CEO; Sustainability; Technology and Innovation.
- Education and credentials: B.E. (Vanderbilt University); CFA charterholder.
Equity Ownership
| As of | Shares Owned Directly/Indirectly | RSUs/Stock Acquirable within 60 Days | Total Beneficial Ownership | Ownership % of Shares Outstanding |
|---|---|---|---|---|
| March 24, 2025 | 2,919 | 2,455 | 5,374 | <1.0% (of 299,856,558 shares outstanding) |
- Outstanding RSUs at 12/31/2024: 2,455 RSUs.
- Trading/pledging restrictions: Directors are prohibited from hedging and pledging company stock; trades restricted to pre-cleared windows or 10b5-1 plans.
- Director stock ownership guidelines: Minimum of five times the value of annual stock grants; 100% post-tax retention until in compliance.
Governance Assessment
- Board effectiveness and engagement: Boze’s prior service as Independent Chair (2018–2023) and current Audit Committee membership suggest strong governance familiarity and financial oversight; attendance met CBRE’s ≥75% aggregate threshold in 2024.
- Independence and conflicts: Independent status confirmed; no related-party transactions involving Boze disclosed for 2024; CBRE enforces robust policies on related-party review, insider trading, hedging/pledging, and director overboarding.
- Ownership alignment: Meaningful equity via annual RSUs and ownership guidelines (5x grant value) foster alignment; RSUs are time-based with clear vesting and no performance metric manipulation risk at the director level.
- RED FLAGS: None observed in proxy disclosure—no pledging, no related-party transactions, no option repricing, Section 16(a) compliance achieved in 2024.